Phase II study of mitoxantrone for liver metastases from breast cancer
- PMID: 2591004
- DOI: 10.1007/BF00694343
Phase II study of mitoxantrone for liver metastases from breast cancer
Abstract
Mitoxantrone was given to 19 patients with liver metastases from breast cancer and biochemical evidence of liver dysfunction. In all, 2 patients received the drug at a dose of 10 mg/m2 on days 1 and 2 of the first course of treatment; 1 patient was given 9 mg/m2 and 17 received 8 mg/m2. Subsequent courses were given at a dose of 10 mg/m2. Three patients (16%) showed a partial response, with time to progression of between 3 and 7 months. Toxicity was considerable, with myelosuppression being the major problem.
Similar articles
-
Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer.Ann Oncol. 1992 Jun;3(6):445-9. doi: 10.1093/oxfordjournals.annonc.a058232. Ann Oncol. 1992. PMID: 1498062
-
Mitoxantrone as second-line single agent in metastatic breast cancer.Oncology. 1991;48(4):265-9. doi: 10.1159/000226940. Oncology. 1991. PMID: 1891166
-
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.J Clin Oncol. 1994 Aug;12(8):1621-9. doi: 10.1200/JCO.1994.12.8.1621. J Clin Oncol. 1994. PMID: 7913721 Clinical Trial.
-
Mitoxantrone: potential for use in intensive therapy.Semin Oncol. 1990 Feb;17(1 Suppl 3):43-8. Semin Oncol. 1990. PMID: 2406923 Review.
-
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.Jpn J Clin Oncol. 1997 Jun;27(3):154-7. doi: 10.1093/jjco/27.3.154. Jpn J Clin Oncol. 1997. PMID: 9255269 Review.
Cited by
-
Breast cancer and liver metastases--incidence, diagnosis and outcome.J R Soc Med. 1992 Aug;85(8):508. J R Soc Med. 1992. PMID: 1404213 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Medical